NCT05269706View on ClinicalTrials.gov

Investigation of the Pharmacokinetic Profile of CBD

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 18, 2022

Primary Completion Date

February 16, 2023

Study Completion Date

February 16, 2023

Conditions
Opioid Use Disorder
Interventions
DRUG

Cannabidiol 200mg

Cannabidiol 200mg (twice daily)

DRUG

Epidiolex

Epidiolex 400mg (twice daily)

DRUG

Cannabidiol 400mg

Cannabidiol 400mg (twice daily)

DRUG

Placebo

Matching Placebo (Twice Daily)

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

Yasmin Hurd

OTHER